Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 3/2011

Open Access 01-06-2011 | Research article

Potent anti-inflammatory and antinociceptive activity of the endothelin receptor antagonist bosentan in monoarthritic mice

Authors: Anne-Katja Imhof, Laura Glück, Mieczyslaw Gajda, Rolf Bräuer, Hans-Georg Schaible, Stefan Schulz

Published in: Arthritis Research & Therapy | Issue 3/2011

Login to get access

Abstract

Introduction

Endothelins are involved in tissue inflammation, pain, edema and cell migration. Our genome-wide microarray analysis revealed that endothelin-1 (ET-1) and endothelin-2 (ET-2) showed a marked up-regulation in dorsal root ganglia during the acute phase of arthritis. We therefore examined the effects of endothelin receptor antagonists on the development of arthritis and inflammatory pain in monoarthritic mice.

Methods

Gene expression was examined in lumbar dorsal root ganglia two days after induction of antigen-induced arthritis (AIA) using mRNA microarray analysis. Effects of drug treatment were determined by repeated assessment of joint swelling, pain-related behavior, and histopathological manifestations during AIA.

Results

Daily oral administration of the mixed ETA and ETB endothelin receptor antagonist bosentan significantly attenuated knee joint swelling and inflammation to an extent that was comparable to dexamethasone. In addition, bosentan reduced inflammatory mechanical hyperalgesia. Chronic bosentan administration also inhibited joint swelling and protected against inflammation and joint destruction during AIA flare-up reactions. In contrast, the ETA-selective antagonist ambrisentan failed to promote any detectable antiinflammatory or antinociceptive activity.

Conclusions

Thus, the present study reveals a pivotal role for the endothelin system in the development of arthritis and arthritic pain. We show that endothelin receptor antagonists can effectively control inflammation, pain and joint destruction during the course of arthritis. Our findings suggest that the antiinflammatory and antinociceptive effects of bosentan are predominantly mediated via the ETB receptor.
Appendix
Available only for authorised users
Literature
1.
Schaible HG, Richter F, Ebersberger A, Boettger MK, Vanegas H, Natura G, Vazquez E, Segond von Banchet G: Joint pain. Exp Brain Res. 2009, 196: 153-162. 10.1007/s00221-009-1782-9.CrossRefPubMed
2.
Boettger MK, Hensellek S, Richter F, Gajda M, Stockigt R, von Banchet GS, Brauer R, Schaible HG: Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target. Arthritis Rheum. 2008, 58: 2368-2378. 10.1002/art.23608.CrossRefPubMed
3.
Brackertz D, Mitchell GF, Mackay IR: Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum. 1977, 20: 841-850. 10.1002/art.1780200314.CrossRefPubMed
4.
Masaki T: Historical review: endothelin. Trends Pharmacol Sci. 2004, 25: 219-224. 10.1016/j.tips.2004.02.008.CrossRefPubMed
5.
Pomonis JD, Rogers SD, Peters CM, Ghilardi JR, Mantyh PW: Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J Neurosci. 2001, 21: 999-1006.PubMed
6.
Stosser S, Agarwal N, Tappe-Theodor A, Yanagisawa M, Kuner R: Dissecting the functional significance of endothelin A receptors in peripheral nociceptors in vivo via conditional gene deletion. Pain. 2010, 148: 206-214. 10.1016/j.pain.2009.09.024.CrossRefPubMed
7.
Zhou Z, Davar G, Strichartz G: Endothelin-1 (ET-1) selectively enhances the activation gating of slowly inactivating tetrodotoxin-resistant sodium currents in rat sensory neurons: a mechanism for the pain-inducing actions of ET-1. J Neurosci. 2002, 22: 6325-6330.PubMed
8.
Khodorova A, Montmayeur JP, Strichartz G: Endothelin receptors and pain. J Pain. 2009, 10: 4-28. 10.1016/j.jpain.2008.09.009.CrossRefPubMed
9.
Khodorova A, Zou S, Ren K, Dubner R, Davar G, Strichartz G: Dual roles for endothelin-B receptors in modulating adjuvant-induced inflammatory hyperalgesia in rats. Open Pain J. 2009, 2: 30-40. 10.2174/1876386300902010030.CrossRefPubMed
10.
11.
Bien S, Riad A, Ritter CA, Gratz M, Olshausen F, Westermann D, Grube M, Krieg T, Ciecholewski S, Felix SB, Staudt A, Schultheiss HP, Ewert R, Volker U, Tschope C, Kroemer HK: The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res. 2007, 67: 10428-10435. 10.1158/0008-5472.CAN-07-1344.CrossRefPubMed
12.
Shaw SG, Boden JP, Biecker E, Reichen J, Rothen B: Endothelin antagonism prevents diabetic retinopathy in NOD mice: a potential role of the angiogenic factor adrenomedullin. Exp Biol Med (Maywood). 2006, 231: 1101-1105.
13.
Boettger MK, Weber K, Schmidt M, Gajda M, Brauer R, Schaible HG: Gait abnormalities differentially indicate pain or structural joint damage in monoarticular antigen-induced arthritis. Pain. 2009, 145: 142-150. 10.1016/j.pain.2009.06.006.CrossRefPubMed
14.
Gruen M, Rose C, Konig C, Gajda M, Wetzker R, Brauer R: Loss of phosphoinositide 3-kinase gamma decreases migration and activation of phagocytes but not T cell activation in antigen-induced arthritis. BMC Musculoskelet Disord. 2010, 11: 63-10.1186/1471-2474-11-63.CrossRefPubMed
15.
Haq A, El-Ramahi K, Al-Dalaan A, Al-Sedairy ST: Serum and synovial fluid concentrations of endothelin-1 in patients with rheumatoid arthritis. J Med. 1999, 30: 51-60.PubMed
16.
Pache M, Schwarz HA, Kaiser HJ, Wuest P, Kloti M, Dubler B, Flammer J: Elevated plasma endothelin-1 levels and vascular dysregulation in patients with rheumatoid arthritis. Med Sci Monit. 2002, 8: CR616-619.PubMed
17.
Yoshida H, Imafuku Y, Ohhara M, Miyata M, Kasukawa R, Ohsumi K, Horiuchi J: Endothelin-1 production by human synoviocytes. Ann Clin Biochem. 1998, 35: 290-294.CrossRefPubMed
18.
Conte Fde P, Barja-Fidalgo C, Verri WA, Cunha FQ, Rae GA, Penido C, Henriques MG: Endothelins modulate inflammatory reaction in zymosan-induced arthritis: participation of LTB4, TNF-alpha, and CXCL-1. J Leukoc Biol. 2008, 84: 652-660. 10.1189/jlb.1207827.CrossRefPubMed
19.
Hamamoto DT, Khasabov SG, Cain DM, Simone DA: Tumor-evoked sensitization of C nociceptors: a role for endothelin. J Neurophysiol. 2008, 100: 2300-2311. 10.1152/jn.01337.2007.CrossRefPubMed
20.
Klass M, Hord A, Wilcox M, Denson D, Csete M: A role for endothelin in neuropathic pain after chronic constriction injury of the sciatic nerve. Anesth Analg. 2005, 101: 1757-1762.CrossRefPubMed
21.
Motta EM, Chichorro JG, Rae GA: Role of ET(A) and ET(B) endothelin receptors on endothelin-1-induced potentiation of nociceptive and thermal hyperalgesic responses evoked by capsaicin in rats. Neurosci Lett. 2009, 457: 146-150. 10.1016/j.neulet.2009.03.055.CrossRefPubMed
22.
Namer B, Hilliges M, Orstavik K, Schmidt R, Weidner C, Torebjork E, Handwerker H, Schmelz M: Endothelin 1 activates and sensitizes human C-nociceptors. Pain. 2008, 137: 41-49. 10.1016/j.pain.2007.08.008.CrossRefPubMed
23.
Daher JB, Souza GE, D'Orleans-Juste P, Rae GA: Endothelin ETB receptors inhibit articular nociception and priming induced by carrageenan in the rat knee-joint. Eur J Pharmacol. 2004, 496: 77-85. 10.1016/j.ejphar.2004.06.012.CrossRefPubMed
24.
Verri WA, Guerrero AT, Fukada SY, Valerio DA, Cunha TM, Xu D, Ferreira SH, Liew FY, Cunha FQ: IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci USA. 2008, 105: 2723-2728. 10.1073/pnas.0712116105.CrossRefPubMed
25.
Chichorro J, Zampronio A, Rae G: Endothelin ET(B) receptor antagonist reduces mechanical allodynia in rats with trigeminal neuropathic pain. Exp Biol Med (Maywood). 2006, 231: 1136-1140.
26.
Griswold DE, Douglas SA, Martin LD, Davis TG, Davis L, Ao Z, Luttmann MA, Pullen M, Nambi P, Hay DW, Ohlstein EH: Endothelin B receptor modulates inflammatory pain and cutaneous inflammation. Mol Pharmacol. 1999, 56: 807-812.PubMed
27.
Khodorova A, Navarro B, Jouaville LS, Murphy JE, Rice FL, Mazurkiewicz JE, Long-Woodward D, Stoffel M, Strichartz GR, Yukhananov R, Davar G: Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med. 2003, 9: 1055-1061. 10.1038/nm885.CrossRefPubMed
28.
Motta EM, Chichorro JG, D'Orleans-Juste P, Rae GA: Roles of endothelin ETA and ETB receptors in nociception and chemical, thermal and mechanical hyperalgesia induced by endothelin-1 in the rat hindpaw. Peptides. 2009, 30: 918-925. 10.1016/j.peptides.2009.01.011.CrossRefPubMed
29.
Piovezan AP, D'Orleans-Juste P, Souza GE, Rae GA: Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation. Br J Pharmacol. 2000, 129: 961-968. 10.1038/sj.bjp.0703154.CrossRefPubMed
30.
Verri WA, Molina RO, Schivo IR, Cunha TM, Parada CA, Poole S, Ferreira SH, Cunha FQ: Nociceptive effect of subcutaneously injected interleukin-12 is mediated by endothelin (ET) acting on ETB receptors in rats. J Pharmacol Exp Ther. 2005, 315: 609-615. 10.1124/jpet.105.089409.CrossRefPubMed
31.
Verri WA, Schivo IR, Cunha TM, Liew FY, Ferreira SH, Cunha FQ: Interleukin-18 induces mechanical hypernociception in rats via endothelin acting on ETB receptors in a morphine-sensitive manner. J Pharmacol Exp Ther. 2004, 310: 710-717. 10.1124/jpet.103.063990.CrossRefPubMed
32.
Yuyama H, Koakutsu A, Fujiyasu N, Fujimori A, Sato S, Shibasaki K, Tanaka S, Sudoh K, Sasamata M, Miyata K: Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. J Cardiovasc Pharmacol. 2004, 44 (Suppl 1): S479-482.CrossRefPubMed
33.
Menendez L, Lastra A, Hidalgo A, Baamonde A: Nociceptive reaction and thermal hyperalgesia induced by local ET-1 in mice: a behavioral and Fos study. Naunyn Schmiedebergs Arch Pharmacol. 2003, 367: 28-34. 10.1007/s00210-002-0655-6.CrossRefPubMed
34.
Verri WA, Cunha TM, Magro DA, Guerrero AT, Vieira SM, Carregaro V, Souza GR, Henriques MG, Ferreira SH, Cunha FQ: Targeting endothelin ETA and ETB receptors inhibits antigen-induced neutrophil migration and mechanical hypernociception in mice. Naunyn Schmiedebergs Arch Pharmacol. 2009, 379: 271-279. 10.1007/s00210-008-0360-1.CrossRefPubMed
Metadata
Title
Potent anti-inflammatory and antinociceptive activity of the endothelin receptor antagonist bosentan in monoarthritic mice
Authors
Anne-Katja Imhof
Laura Glück
Mieczyslaw Gajda
Rolf Bräuer
Hans-Georg Schaible
Stefan Schulz
Publication date
01-06-2011
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2011
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3372

Other articles of this Issue 3/2011

Arthritis Research & Therapy 3/2011 Go to the issue

Research article

Disease activity and low physical activity associate with number of hospital admissions and length of hospitalisation in patients with rheumatoid arthritis

Research article

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study

Editorial

Considering comorbidity in managing rheumatic diseases: going where trials cannot go

Research article

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

Review

Sjögren's syndrome: studying the disease in mice

Editorial

The new era of autoimmune disease research
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits